Summary: Alzheimer’s is a challenging cognitive condition we have yet to understand fully. However, several pharmaceutical companies study the causes, develop early detection methods, and work on potential treatments for the ravaging effects of this neurological disease. This article will showcase the top three Alzheimer’s drug stocks to buy in 2024 through a regulated brokerage like eToro.
Highly Rated Stock Trading & Investing Platform
-
Invest in 2,800+ stocks and other assets including 70+ cryptocurrencies and commodities.
-
0% commission on buying stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
-
Copy top-performing traders in real time, automatically.
-
eToro USA is registered with FINRA for securities trading.
What are Alzheimer’s drug stocks?
About
We still have poor knowledge of Alzheimer’s disease. Still, at its core, it is a neurological disorder that slowly erodes cognitive performance until even the most basic tasks become near impossible.
There is no known cure for the condition, but several pharmaceutical companies develop and produce medication that slow its progress and reduce some symptoms in patients. Investing in such companies provides an opportunity to capitalize on the existing performance and potential breakthroughs in the future.
Additional investing
Top three Alzheimer’s drug stocks to buy
The global Alzheimer’s therapeutics market had a total value of $4.05 billion in 2022, with expectations of a compound annual growth rate (CAGR) of approximately 19.99% until 2030. In other words, investing in Alzheimer’s drug stocks now can potentially lead to lucrative gains in the future.
We present you the choice of the three best Alzheimer’s drug stocks to buy in 2024, according to clinical research, studies, development, trials, and current medication revenue:
To securely buy Alzheimer’s drug stocks, we recommend the following:
1. eToro
- Commission-free stock and ETF trading;
- 2,000+ stocks from 17 exchanges;
- Fractional shares available;
- User-friendly platform.
Highly Rated Stock Trading & Investing Platform
-
Invest in 2,800+ stocks and other assets including 70+ cryptocurrencies and commodities.
-
0% commission on buying stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
-
Copy top-performing traders in real time, automatically.
-
eToro USA is registered with FINRA for securities trading.
1. Biogen
About
Founded in 1978 and headquartered in Cambridge, Massachusets, Biogen is the leading company in neuroscience. Additionally, the company has focused on developing therapies for treating neurological and neurodegenerative conditions like Alzheimer’s and multiple sclerosis.
In June 2021, the FDA gave accelerated approval to Aduhelm, a drug proven to reduce amyloid-beta plaques in the brain, which helps patients with Alzheimer’s, in a move that caused controversy. However, in July 2023, the FDA approved Leqembi, which became the first-ever Alzheimer’s drug to receive full regulatory FDA approval. The drug has shown significant patient improvement and represents a landmark in the broader battle against Alzheimer’s.
Biogen has committed to remain at the helm of innovation and research advancement in tackling Alzheimer’s and other neurological conditions, putting it first among the top Alzheimer’s drug stocks to buy in 2024.
Investing
BIIB stock price today
Your capital is at risk.
2. Eli Lilly
About
Founded in 1867 and based in Indiana, Eli Lilly has established a name for itself by pioneering vanguard treatments like the first polio vaccine and insulin therapy. Today, the pharmaceutical company is known for its antidepressants, Prozac and Cymbalta, and an antipsychotic, Zyprexa.
Eli Lilly has also made breakthroughs in developing an experimental drug, donanemab, which dementia experts claim reduces Alzheimer’s progression in patients, slowing down memory loss and cognitive decline. The company has submitted the drug to the FDA and expects to receive a response by the end of 2023. If successful, the drug would represent a watershed in treating this cognitive disorder and would likely significantly boost the performance of this Alzheimer’s drug stock.
Investing
LLY stock price today
Your capital is at risk.
3. Merck
About
In August 2023, Merck signed a billion-dollar deal with Cerevance to discover new ways to treat Alzheimer’s. The company’s BACE1 drug targeting Alzheimer’s failed its phase 3 in 2018. Still, Merck has re-entered the market with this deal, which, if successful, has the potential to make Merck a key player in this neurodegenerative treatment industry.
Besides Alzheimer’s experimental research, Merck is renowned for the HIV/AIDS drug Isentress, the HPV vaccine Gardasil, and many more. Merck is one of the best drug stocks to watch for in 2024, being an integral component of the Dow Jones Industrial Average and the S&P 100. The company is also listed as 69th on the Fortune 500 and 73rd on the Forbes Global 2000 lists.
Investing
MRK stock price today
Your capital is at risk.
Things to consider when buying Alzheimer’s drug stocks
When investing in Alzheimer’s drug stocks, you need to consider some vital characteristics of the company you are investing in, among the state of its experimental drug trials. Those include:
- The company’s product portfolio and pipeline: While you may be looking for a stock whose performance depends on its Alzheimer’s drugs, make sure that it has other successful products and services. A diversified portfolio mitigates risk and provides stability for your investment;
- Experimental drug trial stages: As there are barely any developed treatments for Alzheimer’s, the clinical trials will make or break your investment. Closely monitor the trial phases of major Alzheimer’s drugs;
- Growth prospects: Clinical development and drug trials are expensive and do not guarantee success, so consider companies that have enough money to finance such endeavors;
- Patents: Patents are everything in Alzheimer’s drugs. Invest in companies with exclusive patent rights to profitable names, brands, and products;
- Leadership: The company’s management board is the kingmaker, as their decisions influence the course of research, clinical trials, and production. Therefore, you should look for a seasoned team with a tradition of success in the neurological treatment industry;
- Partnerships and acquisitions: Collaborations between different pharmaceutical companies help advance the research and development of Alzheimer’s drugs, which became evident with the Biogen-Eisai cooperation.
Pros and cons of investing in Alzheimer’s drug stocks
Investing in Alzheimer’s drug stocks is essentially betting on the success of various clinical drug trials. While the potential for reward is massive, so are the risks involved. Some of the pros and cons of investing in Alzheimer’s drug stocks include:
Pros
- Innovation and research: The neurological industry is rapidly advancing as our population ages, and the demand for vanguard treatment rises. Investing in Alzheimer’s drug research also exposes investors to the cutting-edge technology unlocked by these pharmaceutical companies;
- High demand: With the ongoing demographic trends, we can expect more seniors susceptible to neurological conditions such as Alzheimer’s. This will drive treatment demand, providing significant value for Alzheimer’s drug stocks;
- Market potential and profitability: There are over 55 million people with Alzheimer’s and other forms of dementia worldwide, which makes for a significant potential market in the case of the development of a successful treatment.
Cons
- High risk: Developing an effective Alzheimer’s treatment is a tremendous challenge, with many attempts that failed to pass clinical trials. Investors can find this risk too great for their taste;
- Regulatory obstacles: Getting approval from regulatory bodies like the FDA is problematic as there are many factors to consider in healthcare’s sensitive domain. Additionally, the clinical stages are time-consuming with no guarantees of the results;
- Long development: Timelines of clinical trials and approval for Alzheimer’s drugs extend to many years, requiring enormous sums of money in many steps of the process. This leads to significant delays in investment returns.
- Competitive market: The Alzheimer’s drug development market is fiercely competitive, with multiple companies vying for the same chart pie. This amount of competition can hamper the profitability of any single company.
Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
FAQs about the top three Alzheimer’s drug stocks to buy in 2024
Can you invest in Alzheimer's drug stocks?
Yes, you can invest in Alzheimer’s drug stocks. The top-performing pharmaceutical companies are usually publicly listed.
What are some of the best Alzheimer's drug stocks?
Our choice of the top three Alzheimer’s drug stocks in 2024 for this guide includes Biogen (NASDAQ: BIIB), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK).
Are Alzheimer's drug stocks a risky investment?
All investing bears some risk, and Alzheimer’s drug stocks are especially so due to uncertain clinical trials and ongoing experimental research that will take years to bear fruit.
How do you buy Alzheimer's drug stocks?
You can buy Alzheimer’s drug stocks with an online investing service like eToro.
Highly Rated Stock Trading & Investing Platform
-
Invest in 2,800+ stocks and other assets including 70+ cryptocurrencies and commodities.
-
0% commission on buying stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
-
Copy top-performing traders in real time, automatically.
-
eToro USA is registered with FINRA for securities trading.
